Dr. Nazha on Mutational Model to Predict Response to Hypomethylating Agents in MDS
October 7th 2015Aziz Nazha, MD, hematologist, Leukemia Program at the Cleveland Clinic, Taussig Cancer Institute, discusses results of a mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).
Read More